The Use of DHEA in Women With Premature Ovarian Failure

Early Phase 1WithdrawnNCT01129947

Virginia Center for Reproductive Medicine

Overview

DHEA supplementation has been used in women with infertility and diminished ovarian reserve. There is a small report in 5 women with POF that benefited from the use of DHEA over several months. The investigators aim to evaluate further the use of DHEA in women with Premature ovarian failure (POF).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Premature Ovarian Failure

Interventions

DHEADRUG

DHEA 25 mg tid

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women with POF Exclusion Criteria: * women without ovaries

Locations (1)

Virginia Center for Reproductive Medicine

Reston, Virginia, United States

Outcomes

Primary Outcomes

The Use of DHEA in Women With Premature Ovarian Failure

The following outcomes will be evaluated: FSH, AMH, estradiol, ovarian volume, antral follicle count, pregnancy in women seeking to conceive

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.